Literature DB >> 21290264

Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.

Johannes Järhult1.   

Abstract

A 65-year-old woman on anastrozole treatment because of a recurrent breast cancer developed hypercalcaemia and increased parathyroid hormone (PTH) levels 2½ years after start of the treatment. A diagnosis of hyperparathyroidism was suspected and the patient underwent neck surgery, but only normal parathyroid glands were found. Postoperatively, the hypercalcaemia as well as the PTH level continued to rise, and 9 months after exploration of the parathyroids her calcium level was extremely high (adjusted serum calcium = 3.39 mmol/l). Anastrozole was then withheld, and within 2 weeks the severe hypercalcaemic state turned into hypocalcaemia. A month later, anastrozole treatment was started again, and after 6 weeks her calcium and PTH values had returned to extremely high levels. After withdrawal of anastrozole, calcium and PTH concentrations again fell toward normal values. The urinary excretion of calcium was very low during anastrozole treatment and high after cessation of the drug. The mechanism(s) by which anastrozole can cause hypercalcaemia are unknown. However, it might be hypothesised that anastrozole, directly or indirectly, interferes with the calcium-sensing receptors known to be present on the cell surface of both parathyroid and renal tubular cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290264     DOI: 10.1007/s12282-011-0253-x

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  2 in total

1.  Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism.

Authors:  Run Yu
Journal:  Endocrine       Date:  2016-07-01       Impact factor: 3.633

2.  PRIMARY HYPERPARATHYROIDISM AND SERUM CALCIUM IN BREAST CANCER PATIENTS EVALUATED FOR LOW BONE MASS - A SINGLE CENTER EXPERIENCE.

Authors:  Marija Punda; Petra Petranović Ovčariček; Anita Tabain; Klaas Pieter Koopmans; Gabriela Alfier; Tomislav Jukić; Ana Fröbe
Journal:  Acta Clin Croat       Date:  2021-12       Impact factor: 0.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.